GSK is acquiring lung cancer biotech Nuvalent in its biggest deal in over a decade

GSK is acquiring lung cancer biotech Nuvalent in its largest deal in over a decade. The all-cash transaction provides GSK with two late-stage lung cancer drugs under FDA review.